A simulation model to estimate 10-year risk of coronary heart disease events in patients with schizophrenia spectrum disorders treated with second-generation antipsychotic drugs

Annals of Clinical Psychiatry

Volumn 25, Issue 1, 2013, Pages 17-26

  Darbà, Josep ^a   Kaskens, Lisette ^b   Aranda, Pedro ^c   Arango, Celso ^d   Bobes, Julio ^e,f   Carmena, Rafael ^g   Rejas, Javier ^h  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Health Economics and Outcomes Research   (Spain)

^c HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^f UNIVERSITY OF OVIEDO   (Spain)

^g HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^h PFIZER INC   (United States)

Author keywords

Cardiovascular events; Coronary heart disease; Framingham function; Modeling schizophrenia; Second generation antipsychotics

Indexed keywords

OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL STUDY; DISEASE DURATION; FEMALE; FRAMINGHAM RISK SCORE; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RISK ASSESSMENT; SCHIZOPHRENIA; SIMULATION; STOCHASTIC MODEL; TREATMENT DURATION;

ADULT; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; CORONARY DISEASE; FEMALE; HUMANS; MALE; MARKOV CHAINS; METABOLIC PHENOMENA; MIDDLE AGED; MODELS, STATISTICAL; MORTALITY; RISK ASSESSMENT; RISK FACTORS; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 84878744389     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Kannel WB. Contributions of the Framingham Study to the conquest of coronary artery disease. Am J Cardiol. 1988;62:1109-1112. (Pubitemid 18267575)
2. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847. (Pubitemid 28213628)
3. Grundy SM, Bazzarre T, Cleeman J, et al. Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: medical office assessment: Writing Group I. Circulation. 2000;101:E3-E11.
4. Pocock SJ, McCormack V, Gueyffier F, et al. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials. BMJ. 2001;323:75-81. (Pubitemid 32681971)
5. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry. 2000; 177:212-217.
6. Babidge NC, Buhrich N, Butler T. Mortality among homeless people with schizophrenia in Sydney, Australia: a 10-year follow-up. Acta Psychiatr Scand. 2001;103:105-110. (Pubitemid 32147130)
7. Hiroeh U, Appleby L, Mortensen PB, et al. Death by homicide, suicide, and other unnatural causes in people with mental illness: a population-based study. Lancet. 2001;358:2110-2112. (Pubitemid 34094900)
8. Morgan MG, Scully PJ, Youssef HA, et al. Prospective analysis of premature mortality in schizophrenia in relation to health service engagement: a 7.5-year study within an epidemiologically complete, homogeneous population in rural Ireland. Psychiatry Res. 2003;117:127-135. (Pubitemid 36246708)
9. Bobes J, Rejas J, Garcia-Garcia M, et al. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophr Res. 2003;62:77-88. (Pubitemid 36588706)
10. De Hert MA, van Winkel R, Van Eyck D, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res. 2006;83:87-93.
11. Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150:1115-1121. (Pubitemid 41773510)
12. Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry. 2003;160:290-296. (Pubitemid 41110454)
13. Van Gaal LF. Long-term health considerations in schizophrenia: metabolic effects and the role of abdominal adiposity. Eur Neuropsychopharmacol. 2006; 16:S142-S148. (Pubitemid 44177766)
14. Basu R, Brar JS, Chengappa KN, et al. The prevalence of the metabolic syndrome in patients with schizoaffective disorder-bipolar subtype. Bipolar Disord. 2004;6:314-318. (Pubitemid 39077092)
15. Meyer JM, Nasrallah HA, McEvoy JP, et al. The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res. 2005;80:9-18. (Pubitemid 41587459)
16. Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005;80:45-53. (Pubitemid 41587462)
17. Centers for Disease Control and Prevention (CDC). Prevalence of coronary heart disease-United States, 2006-2010. MMWR Morb Mortal Wkly Rep. 2011;60:1377-1381.
18. Dawber TR, Meadors GF, Moore FE Jr. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health Nations Health. 1951;41:279-281.
19. Marrugat J, Solanas P, D'Agostino R, et al. Coronary risk estimation in Spain using a calibrated Framingham function [in Spanish]. Rev Esp Cardiol. 2003;56:253-261. (Pubitemid 36527246)
20. Aranceta J, Pérez Rodrigo C, Foz Sala M, et al. Tables of coronary risk evaluation adapted to the Spanish population: the DORICA study [in Spanish]. Med Clin (Barc). 2004;123:686-691. (Pubitemid 40068835)
21. Cristóbal J, Lago F, de la Fuente J, et al. Comparison of coronary risk estimates derived using the Framingham and REGICOR equations [in Spanish]. Rev Esp Cardiol. 2005;58:910-915. (Pubitemid 41419166)
22. Bobes J, Arango C, Aranda P, et al. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res. 2007;90:162-173. (Pubitemid 46177553)
23. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223. (Pubitemid 41345943)
24. Ministry of Health, Social Services and Equality. Series 1981-2007: Mortality by cause of death, Spain and regions [in Spanish]. http://www.msc.es/estadEstudios/estadisticas/estadisticas/estMinisterio/ mortalidad/seriesTablas.htm. Accessed September 20, 2012.
25. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906. (Pubitemid 41265663)
26. Darbà J. Use of probabilistic methods in economic evaluation of health technologies [in Spanish]. Gac Sanit. 2006;20:74-77. (Pubitemid 43436543)
27. Altamura AC, Bobo WV, Meltzer HY. Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment. Int Clin Psychopharmacol. 2007;22:249-267. (Pubitemid 47237544)
28. Michelsen JW, Meyer JM. Cardiovascular effects of antipsychotics. Expert Rev Neurother. 2007;7:829-839. (Pubitemid 47037723)
29. Osby U, Correia N, Brandt L, et al. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res. 2000;45:21-28.
30. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis. 2006;3:A42.
31. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19-32. (Pubitemid 41587460)
32. Cohn T, Prud'homme D, Streiner D, et al. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry. 2004;49:753-760. (Pubitemid 40094948)
33. Hägg S, Lindblom Y, Mjörndal T, et al. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol. 2006;21:93-98. (Pubitemid 43740316)
34. De Hert M, van Winkel R, Van Eyck D, et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemiol Ment Health. 2006;2:14.
35. Heeg B, Buskens E, Knapp M, et al. Modelling the treated course of schizophrenia: development of a discrete event simulation model. Pharmacoeconomics. 2005;23:17-33.
36. Eklund M, Bäckström M. A model of subjective quality of life for outpatients with schizophrenia and other psychoses. Qual Life Res. 2005;14:1157-1168. (Pubitemid 40685238)
37. Morris BJ, Cochran SM, Pratt JA. PCP: from pharmacology to modelling schizophrenia. Curr Opin Pharmacol. 2005;5:101-106. (Pubitemid 40124542)
38. Woodward TS, Menon M, Hu X, et al. Optimization of a multinomial model for investigating hallucinations and delusions with source monitoring. Schizophr Res. 2006;85:106-112. (Pubitemid 43947527)
39. Schwegler H. Phenomenological modelling of some mechanisms in schizophrenia. Pharmacopsychiatry. 2006;39:S43-S49. (Pubitemid 43357105)